Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2960320

N.O=C(O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1cccc(Cl)c1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 6/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 2/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 1/20 0.37
GFER P55789 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RAB9A P51151 2/20 0.37
HTT P42858 1/20 0.37
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
CSNK2A1 P68400 2/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952784 0.91 NPC1 (0.41) NPC1RXFP1TDP1MAPTTP53
Ammonia Solution, Strong SCHEMBL1267334 0.89 CDK4 (0.38) MAPTTP53KMT2AMEN1LMNA
Ammonia Solution, Strong SCHEMBL2956251 0.87 MAPT (0.41) NPC1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL2952196 0.86 MAPT (0.52) NPC1TDP1MAPTKMT2AMEN1
SCHEMBL2953084 0.86 ALDH1A1 (0.42) NPC1MAPTPKMKMT2AMEN1
Ammonia Solution, Strong SCHEMBL2958892 0.83 CHRNA7 (0.35) MAPTKMT2AMEN1LMNA
SCHEMBL2958025 0.82 DHODH (0.37) MAPTTP53KMT2AMEN1RAB9A
Ammonia Solution, Strong SCHEMBL2960210 0.82 NPC1 (0.39) NPC1RXFP1TDP1MAPTTP53
SCHEMBL2954060 0.81 NPC1 (0.37) NPC1RXFP1TDP1MAPTTP53
SCHEMBL1266478 0.81 CHRNA7 (0.35) MAPTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK NPC1 2692/4885RXFP1 503/4885TDP1 1445/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 NPC1 2803/4885RXFP1 471/4885TDP1 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.